| |
Latest 10 SEC filings (by transaction date) for PCYN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Aug 21/23 | Jul 31/23 | Suggs Fred Wilson Jr | Direct Ownership | Stock Option | A - Grant, award or other under Rule 16b-3(d) | 25,432 | $0.248 |
Aug 2/23 | Jul 31/23 | Treshler Joseph Raymond | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 8,000 | $0.250 |
Aug 2/23 | Jul 31/23 | McCullough Monica | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 7,200 | $0.250 |
Aug 2/23 | Jul 31/23 | McComas Steven | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 5,600 | $0.250 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for PCYN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Aug 21/23 | Jul 31/23 | Suggs Fred Wilson Jr | Direct Ownership | Stock Option | A - Grant, award or other under Rule 16b-3(d) | 25,432 | $0.248 |
Aug 2/23 | Jul 31/23 | Treshler Joseph Raymond | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 8,000 | $0.250 |
Aug 2/23 | Jul 31/23 | McCullough Monica | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 7,200 | $0.250 |
Aug 2/23 | Jul 31/23 | McComas Steven | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 5,600 | $0.250 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Eyepoint Pharmaceuticals (OQ:EYPT) |
AbbVie (N:ABBV) |
Merck & Co (N:MRK) |